Stock Events

Stock Events

Finch Therapeutics Group 

$7.45
5
-$0.47-5.9% Monday 13:30

Statistics

Day High
7.45
Day Low
7.45
52W High
14.56
52W Low
6.21
Volume
-
Avg. Volume
-
Mkt Cap
11.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-69,863.55%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
214,000Revenue
-149.51MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FNCH. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regenxbio
RGNX
Mkt Cap311.74M
REGENXBIO Inc. is involved in gene therapy, which overlaps with Finch Therapeutics' approach to treating chronic diseases, including those related to the microbiome.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Vertex Pharmaceuticals Incorporated works on creating transformative medicines for people with serious diseases, including genetic therapies that could compete with Finch's microbiome-based treatments.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics AG focuses on gene editing, a cutting-edge area of biotech that could rival Finch Therapeutics' microbiome-based approaches in treating genetic disorders.
Novartis
NVS
Mkt Cap292.07B
Novartis AG, a large pharmaceutical company, has a broad interest in innovative therapeutic approaches, including gene and cell therapies, which could compete with Finch's microbiome therapies.
Biogen
BIIB
Mkt Cap29.53B
Biogen Inc. has a strong focus on neurodegenerative diseases, an area where Finch Therapeutics could make inroads with its microbiome-based treatments.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. is known for its work in antiviral drugs but is expanding into other therapeutic areas, potentially competing with Finch Therapeutics in the microbiome space.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. is a biotech giant that explores various therapeutic areas, including those that could overlap with Finch Therapeutics' focus on microbiome and chronic diseases.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc., with its wide range of pharmaceutical products and research into new therapies, could become a competitor as it explores the microbiome's role in health and disease.

About

Finch Therapeutics Group, Inc. is a U.S.-based, clinical-stage biotechnology company dedicated to developing innovative, orally administered biological drugs that leverage the microbiome. Its leading investigational therapy, CP101, is an orally delivered microbiome capsule currently in Phase 3 clinical trials. This candidate aims to treat patients suffering from recurrent Clostridioides difficile infection, as well as chronic hepatitis B virus. The company's pipeline also features FIN-211, an oral enriched consortia product candidate being developed for the treatment of autism spectrum disorder. Additionally, Finch is advancing TAK-524 and FIN-525, which are targeted oral consortia product candidates for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Finch Therapeutics maintains strategic collaboration and licensing agreements with partners such as Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota. Founded in 2014, Finch Therapeutics Group, Inc. operates from its headquarters in Somerville, Massachusetts.
Show more...
CEO
Mr. Matthew P. Blischak J.D.
Employees
1
Country
United States
ISIN
US31773D2009

Listings

OTC Link
US
FNCHQ
OTCM
US
FNCH

0 Comments

Share your thoughts

FAQ

What is Finch Therapeutics Group stock price today?▼
The current price of FNCH is $7.45 USD — it has decreased by -5.9% in the past 24 hours. Watch Finch Therapeutics Group stock price performance more closely on the chart.
What is Finch Therapeutics Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Finch Therapeutics Group stocks are traded under the ticker FNCH.
Is Finch Therapeutics Group stock price growing?▼
FNCH stock has risen by +0% compared to the previous week, the month change is a -5.9% fall, over the last year Finch Therapeutics Group has showed a -45.82% decrease.
What is Finch Therapeutics Group market cap?▼
Today Finch Therapeutics Group has the market capitalization of 11.96M
When is the next Finch Therapeutics Group earnings date?▼
Finch Therapeutics Group is going to release the next earnings report on August 13, 2026.
What is Finch Therapeutics Group revenue for the last year?▼
Finch Therapeutics Group revenue for the last year amounts to 214,000 USD.
What is Finch Therapeutics Group net income for the last year?▼
FNCH net income for the last year is -149.51M USD.
How many employees does Finch Therapeutics Group have?▼
As of June 15, 2026, the company has 1 employees.
In which sector is Finch Therapeutics Group located?▼
Finch Therapeutics Group operates in the Health & Wellness sector.
When did Finch Therapeutics Group complete a stock split?▼
The last stock split for Finch Therapeutics Group was on June 12, 2023 with a ratio of 1:30.
Where is Finch Therapeutics Group headquartered?▼
Finch Therapeutics Group is headquartered in Boston, United States.